| Company Name: | Genelabs Technologies, Incorporated | | Ticker Symbol: | GNLB | | | WWW Address: | www.genelabs.com |
| CEO: | Frederick W. Driscoll | | No. of Employees: | 76 |
| Common Issue Type: | CS | | Business Description: | A biopharmaceutical company is engaged in the discovery and development of infectious disease therapies to improve human health.
|
| | | Industry Information: | DRUGS - Diagnostic Support [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.29 |  0.0 | - | - | | 1.30 | 1.29 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 56.6 | 43.9 | -2.97 | -0.07 | 0.00 | 0.0 | 0.0 | 1.52 - 0.21 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.29 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 56.6 | mil |
| Latest Shares Outstanding | 43.9 | mil |
| Earnings pS (EPS) | -0.07 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 222,105 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 43.6 | mil |
| Float as % of Shares Outstanding | 99.3 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 67.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 139.60 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | -98.4 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | -40.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -46.4 | % |
| Current Ratio | 10.0 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.50 | $ |
| Cash pS | 0.55 | $ |
| Book-Value pS | 0.55 | $ |
| Tangible Book-Value pS | 0.55 | $ |
| Cash Flow pS | -0.24 | $ |
| Free Cash Flow pS | -0.41 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.35 | |
| Price/Tangible Book Ratio | 2.35 | |
| Price/Cash Flow | -5.4 | |
| Price/Free Cash Flow | -3.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 102 | 434 | 788 |
| 4 Weeks | 1.30 | 1.28 | 1.29 | 0.0 | 97 | 1,206 | 20,503 |
| 13 Weeks | 1.30 | 0.21 | 0.39 | 230.8 | 327 | 6,015 | 366,901 |
| 26 Weeks | 1.30 | 0.21 | 0.65 | 98.5 | 270 | 3,552 | 444,017 |
| 52 Weeks | 1.52 | 0.21 | 1.49 | -13.4 | 133 | 2,380 | 595,030 |
| YTD | 1.30 | 1.28 | - | 0.0 | 99 | 206 | 1,031 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.29 | 1.29 | 1.21 | 0.76 | 0.79 | -2.97 | -3.83 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 36.80 | 85.3 | 20.47 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 24.22 | NA | 60.99 |
| R&D | -1.20 | NA | 6.34 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -42.5 | -93.5 | 50.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.20 | -0.11 | 0.34 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 73.00 |
| Current Ratio | 4.6 |
| Quick Ratio (Acid Test) | 4.6 |
| Liquidity Ratio (Cash) | 4.36 |
| Receivables Turnover | 11.2 |
| Average Collection Period | 32 |
| Working Capital/Equity | 95.7 |
| Working Capital pS | 0.72 |
| Cash-Flow pS | -0.04 |
| Free Cash-Flow pS | -0.33 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.35 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 23.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 4.8 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.56 |
| Tobin's Q Ratio | 1.32 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -6.69 |
| Enterprise Value (EV)/Free Cash Flow | -2.51 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.35 |
| Price/Book Ratio - LTM | 2.35 |
| Price/Cash Flow Ratio | -5.4 |
| Price/Free Cash Flow Ratio - LTM | -3.1 |
| Price/Sales Ratio | 4.96 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.20 |
| Tangible Book Value pS - LTM | 0.55 |
| Book Value pS - LTM | 0.55 |
| Capital Invested pS | 0.75 |
| Cash pS - LTM | 0.55 |
| Cash Flow pS - LTM | -0.24 |
| Free Cash Flow pS - LTM | -0.41 |
| Earnings pS (EPS) | -0.07 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -84.83 |
| Free Cash Flow Margin 5YEAR AVG | -227.88 |
| Net Profit Margin | -13.8 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.52 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.52 |
| Return on Capital Invested (ROCI) | -7.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -74.8 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | -5.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -40.3 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | -98.4 |
| Pre-Tax Profit Margin | -13.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 44 |
| Revenue per Employee | 222,105 |
| Net Income per Employee | -30,724 |
| Average Collection Period | 44 |
| Receivables Turnover | 11.2 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 8.47 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 0.54 |
| Fixed Assets Turnover | 5.69 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 0.45 |
| Revenue per $ Plant | 5.91 |
| Revenue per $ Common Equity | 0.52 |
| Revenue per $ Capital Invested | 0.52 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 40.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 74.0 |
| Research & Devlopment (R&D) as % of Revenue | 88.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 88.8 |
|
|  
|
| |
 |  |
